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Summary This study examined the association between 17p allelic loss, p53gene mutation, p53 protein expression and DNA aneuploidy in
a series of adenocarcinomas arising in the oesophagus and gastric cardia. 17p allelic loss was detected in 79% (15 of 19) of oesophageal and
in 83% (29 of 35) of gastric adenocarcinomas. p53 mutations were detected in 70% (14 of 20) and 63% (26 of 41) of oesophageal and of
gastric adenocarcinomas respectively. Both tumour types were associated with a predominance of base transitions at CpG dinucleotides. In
five cases of oesophageal adenocarcinoma, the same mutation was detected both in tumour and in adjacent dysplastic Barrett's epithelium.
Diffuse p53 protein expression was detected in 65% (13 of 20) and 59% (24 of 41) of oesophageal and of gastric tumours, respectively, and
was associated with the presence of p53 missense mutation (Chi-squared, P < 0.0001). DNA aneuploidy was detected in 80% (16 of 20) of
oesophageal and in 70% (28 of 40) of gastric tumours. No association was found between p53 or DNA content abnormalities and tumour
stage or histological subtype. In conclusion, this study detected a similar pattern of p53 alterations in adenocarcinoma of the oesophagus and
gastric cardia - molecular data consistent with the observation that these tumours demonstrate similar clinical and epidemiological features.
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Inrecentyears, theincidencerates ofadenocarcinomaoftheoesoph-
agus and gastric cardia have increased steadily, while there has been
a decrease in the proportion oftumours arising in the distal stomach
(Powell and McConkey, 1990; Blot et al, 1991). Gastric adeno-
carcinomas represent a heterogeneous group of tumours. Adeno-
carcinomas arising in the proximal stomach (gastric cardia) were
reported to demonstrate biological and epidemiological features
distinct from those arising in the distal stomach (gastric antrum)
(Sidoni etal, 1989; Blot etal, 1991). Conversely, adenocarcinoma of
the gastric cardia was reported to demonstrate clinicopathological
features similar to those ofoesophageal adenocarcinoma (Kalish et
al, 1984; Wang et al, 1986). These data suggest that tumours arising
in different anatomical sites in the stomach are associated with
distinct aetiologies, while adenocarcinomas arising in the oesoph-
agus and gastric cardia may share similaraetiologies.
The specific aetiological factors underlying the increasing inci-
dence of adenocarcinoma of the oesophagus and gastric cardia
remain unresolved. Barrett's oesophagus, a condition in which the
squamous epithelium normally lining the lower oesophagus is
replaced by a metaplastic columnar epithelium, represents one
known risk factor for oesophageal adenocarcinoma. This condition
arises in 10-12% of patients with chronic gastro-oesophageal
reflux (Winters et al, 1987). The estimated risk of a patient with
Barrett's oesophagus developing adenocarcinoma is 30 to 40 times
higher than in the general population (Spechler et al, 1984).
Tumour development in these patients is proposed to occur via a
series of dysplastic cell changes, recognized histologically as a
metaplasia-dysplasia-carcinoma sequence (Thompson etal, 1983).
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The p53 gene, localized to chromosome 17pl3 (McBride et al,
1986), encodes a 53-kDa nuclear phosphoprotein that functions in
a signal transduction pathway, causing an arrest of cells in the G,
phase of the cell cycle in response to DNA damage (Kastan et al,
1991). Allelic loss on chromosome 17p and p53 gene mutations
are among the most common genetic abnormalities documented in
human cancers (Greenblatt et al, 1994). The majority ofp53 muta-
tions have been reported to occur in exons 5-8, corresponding to
the evolutionarily conserved domains of the protein (Soussi et al,
1990; Greenblatt et al, 1994). Mutations in these domains were
found to be associated with loss of wild-type p53 function,
including growth suppression (Martinez et al, 1991). Inactivation
of p53 was reported to be associated with the development of
genomic instability and DNA aneuploidy (Livingstone et al, 1992;
Yin et al, 1992; Carder et al, 1993).
p53 and DNA content abnormalities have been implicated in the
development of both oesophageal and gastric adenocarcinoma
(Reid et al, 1987; Yonemura et al, 1992; Blount et al, 1993; Renault
et al, 1993; Hamelin et al, 1994). However, molecular studies in
which gastric tumours were analysed with respect to anatomical
site of origin (cardia vs antrum) have reported a number of site-
specific differences. Significantly higher levels of p53 protein
expression (Flejou et al, 1994) and DNA aneuploidy (Johnson et al,
1993; Flejou et al, 1994) have been reported in gastric cardia
tumours compared with tumours arising in the gastric antrum.
These molecular data are consistent with the observation that prox-
imal and distal gastric tumours display distinct epidemiological
features (Blot et al, 1991). Conversely, adenocarcinoma of the
oesophagus and gastric cardia demonstrate similar clinical and
epidemiological features (Wang et al, 1986; Blot et al, 1991). The
aim ofthe present study was, firstly, to document the pattern ofp53
and DNA content abnormalities in a homogenous series of adeno-
carcinomas arising in the gastric cardia and to compare the pattern
with that detected in a series of oesophageal adenocarcinomas.
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Table 1 PCR amplification and sequencing primers for p53, exons 5-8
p53 Primer sequences Application: PCR and/or sequencinga
Exon 5 5'-TGTTCACTTGTGCCCTGACT-3' Left PCR and sequencing primer
5'-AGCAATCAGTGAGGAATCAG-3' Right PCR and sequencing primer
Exon 6 5'-TGGTTGCCCAGGGTCCCCAG-3' Left PCR and sequencing primer
5'-GGAGGGCCACTGACAACCA-3' Right PCR and sequencing primer
Exon 7 5'-CTTGCCACAGGTCTCCCCAA-3' Left PCR and sequencing primer
5'-AGGGGTCAGCGGCAAGCAGA-3' Right external PCR primer
5'-TGTGCAGGGTGGCMGTGGC-3' Right internal sequencing primer
Exon 8 5'-TTCCTTACTGCCTCTTGCTT-3' Left PCR and sequencing primer
5'-AGGCATAACTGCACCCTTGG-3' Right PCR and sequencing primer
aSequence analysis of exons 5, 6 and 8 used the same primers as those used for PCR amplification. For exon 7, an
internal primer was used in the reverse direction to give optimal sequencing profiles.
Table 2 17p allelic loss, p53 gene mutation, p53 protein expression and DNA content in Barrett's epithelium and oesophageal adenocarcinoma
LOH at 17p13c p53Mutation analysis
Patient Stagea Histologyb D17S 513 D17S796 SSCPd Codon Nucleotide Nature of Amino acid ICC9 DNA content Dih
no. change nucleotide change
substitution
104 W/MD a H 6 196 CGA -o TGA G:C to A:Te Arg -o Stop -ve Aneuploid 1.3
108 MD b H 6 212 2-bp Deletion Frameshift -ve Aneuploid 1.5
HGD - H 6 212 2-bp Deletion Frameshift -ve -
LGD - H -ve
im - H -ve
90 IIA WD H a 8 273 C£T - CAT G:C to A:Te Arg - His + + + Aneuploid 3.2
36 IIB WD H - -ve + Aneuploid 1.8
88 IIA W/MD b H 8 282 CGG - TGG G:C to A:Te Arg - Trp + + + Aneuploid 1.8
110 IIA MD ab H -ve -ve Diploid 1.0
112 IIA MD b a 5 158 C(-C CTC G:C to T:A Arg-Leu + + + Aneuploid 1.4
125 IIA MD b b -ve -ve Aneuploid 1.6
HGD - b -ve -ve -
76 IIB MD a H 8 282 CGG -- IGG G:C to A:Te Arg - Trp ++ + Aneuploid 1.5
HGD - H 8 282 CGG-TGG G:C to A:Te Arg-Trp +++ -
22 IIA PD b - 7 248 CGG - TGG G:C to A:Te Arg - Trp + + + Aneuploid 1.3
HGD - - 7 248 QGG+ TGG G:Cto A:Te Arg - Trp +++ -
120 IIA PD a - 5 N.D. ++ + Aneuploid 2.3
123 IIA PD ab ab 8 266 GGA GAGM G:Cto A:T Gly-Glu + + + Diploid 1.0
109 11 PD b - 5 175 CGC- CAC G:Cto A:Te Arg-His ++ + Diploid 1.0
54 III MD ab H -ve + Diploid 1.0
99 III MD H b 7 248 CGG - _GG G:C to A:Te Arg - Trp ++ + Aneuploid 1.4
124 III MD H b 8 285 GAG-AAG G:Cto A:T Glu-Lys ++ + Aneuploid 1.4
HGD - b 8 285 £AG-AAG G:Cto A:T Glu-Lys ++ + -
29 III M/PD ab ab 5 175 CGC-CAC G:Cto A:Te Arg-His ++ + Aneuploid 1.4
HGD - ab 5 175 CQC *CAC G:Cto A:Te Arg-His + + +
LGD - ab 5 175 CGC-CAC G:Cto A:Te Arg-His .+++ +
im - ab -ve -ve
50 III PD H b 7 242 TGC TTC G:Cto T:A Cys - Phe ++ + Aneuploid 1.7
74 III PD b b 7 248 CGG C GAG G:C to A:Te Arg -- Gln ++ + Aneuploid 1.6
43* IlIl PD b b -ve -ve Aneuploid 1.7
aTNM - stage 1: 1, 0, 0; stage IIA: 2, 0, 0/3, 0, 0; stage IIB: 1, 1, 0/2, 1, 0; stage III: 3, 1, 0/4, 0, 0. bThe tumours were classified according to the procedure of
Lauren (1965). *Tumour no. 43 was a diffuse-type adenocarcinoma. All other tumours were intestinal-type adenocarcinoma arising on a background of Barrett's
metaplasia. WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; HGD, high-grade dysplasia; LGD, low-grade dysplasia; im, intestinal
metaplasia. ca, Upper allele retained; b, lowerallele retained; ab, heterozygous with no loss; H, homozygous; -, not determined. dExon exhibiting band shift. -ye,
band shift not detected. 8G:C to A:T base transitions occurring at CpG dinucleotides. 'Predicted change in amino acid sequence as a result of mutation. slCC,
immunohistochemistry; +, < 10% positive cells, focal staining pattern; ++, 10-50% positive cells; +++, > 50% positive cells, diffuse staining pattern; -ve,
negative. hDI, DNA index.
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Table 3 17p allelic loss, p53 gene mutation, p53 protein expression and DNA content in gastric adenocarcinoma
LOH at 17p13c p53 mutation analysis
Patient Stagea Histologyb D17S 513 DI17S796 SSCPd Codon Nucleotide Nature of Amino acid lCC9 DNA content Dlh
no. change nucleotide change'
substitution
105 IIA l,WD a H 8 273 CGT-CTGT G:CtoA:Te Arg-4Cys .+.+ Diploid 1.0
37 IIA l,WD b b 6 215 AGT-*AGG A:TtoC:G Ser- Arg +++ Aneuploid 1.6
52 IIA l,WD H ab -ye +++ Diploid 1.0
72 IIA MD a - v-e -ye Aneuploid 1.6
121 IIA 1,MD a a 6 193 CAT-*CIT A:TtoT:A His-dLeu .+.+ Aneuploid 1.5
95 IIA 1, MD H H 8 306 CGA -*TGA G:C to A:Te Arg -*Stop -ye Aneuploid 1.6
31 IIA 1,MD H b 8 282 _QGG-+TGG G:CtoA:Te Arg-*Trp +++ Diploid 1.0
30 IIA MD b - v-e ++ Diploid 1.0
92 lIB I, MD b b 7 248 CG -G CAG G:C to A:Te Arg -~Gin +++ Aneuploid 1.2
85 lIB 1,PD a a 5 175 CQC-*CAC G:CtoA:Te Arg-*His +++ Diploid 1.0
6(C+T) 213 CGA-CCGG Arg->Arg
98 IIA D, PD H H 5 146 TGQ-*TGA G:CtoA:T Trp- Stop -ye Aneuploid 1.5
48 III l,WD H a -ye + Aneuploid 1.2
21 III l,WD -b -ye + + + Aneuploid 1.6
24 III I,WD -a 5 173 QTG-+TTG G:CtoT:A Val->Leu +++ Aneuploid 1.4
83 III 1,MD a - 5 173 aTG-4ATG G:CtoA:T Val- Met +++ Aneuploid 1.4
111 Ill MD b a 5 175 CG-C-CAC G:CtoA:Te Arg-*J-lis +++ Aneuploid 1.4
68 Ill 1, MD H ab -ye + + Aneuploid 1.8
77 Ill I, MD ab - v-e + Diploid 1.0
75 Ill MD H - v-e -ye Aneuploid 1.4
97 Ill 1, PD H ab -ye + Aneuploid 1.3
35 Ill PD b H -ye +++ Aneuploid 2.6
103 Ill PD -b 7 249 A-GG ATG G:CtoT:A Arg-4Met +++ Aneuploid 1.6
127 Ill PD a a 7 245 _QGC-*AGC G:CtoA:Te Gly- Ser +++ Diploid 1.0
107 Ill PD b b 5 138 GQC-C GTC G:CtoA:T Ala-*Val +++ Aneuploid 1.6
115 Ill PD -- 8 273 C-QT-CAT G:CtoA:Te Arg-CHis +++ Aneuploid 1.3
44 Ill I, PD H ab -ye +/++ Diploid 1.0
94 Ill 1, PD ab a -ye + Aneuploid 1.8
100 Ill PD H b 8 282 CGG-*TGG G:CtoA:Te Arg-*Trp +++ Diploid 1.0
122 Ill 1, PD H b 8 273 CGT -4CAT G:C to A:Te Arg -*His + + + Aneuploid 2
40 ill PD b - -ye + + + Aneuploid 1.2
69 ill 1, PD ab - 8 306 QGA -* TGA G:C to A:Te Arg -~Stop -ye No result -
89 Ill 1, PD a - 8 Sds gt -* at -ye Aneuploid 1.4
93 Ill PD - - -ye -ye Aneuploid 1.2
67 Ill D,PD H a 5 168 CAC-*CGC A:TtoG:C His-*Arg +++ Aneuploid 1.6
102 Ill D,PD H a -ye +++ Diploid 1.0
84 Ill D, PD H b 6 222 9-bp Deletion + Aneuploid 1.9
38 Ill D, PD b b 8 266 GG-A *GMA G:C to A:T Gly -~Glu +++ Aneuploid 2.0
116 Ill D,PD H H 7 245 GG-C-GAC G:CtoA:T Gly- Asp +++ Diploid 1.0
81 Ill D,PD H b 7 Sds gt-*tt -ye Diploid 1.0
58 Ill D, PD b a 6 Sds gt -* at -ye Aneuploid 1.3
101 Ill D,PD a b 8 273 CGT->ITGT G:CtoA:Te Arg->Cys +++ Aneuploid 1.5
aTNM - stage IIA: 2, 0, 0/3, 0, 0; stage IIB: 1,1, 0/2,1, 0; Stage Ill: 3,1, 0/4, 0, 0. bThe tumours were classified according to the procedure of Lauren (1965). 1,
intestinal type; D, diffuse type; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated. ca, Upper allele retained; b, lower allele retained;
ab, heterozygous with no loss; H, homozygous; -, not determined. dExon exhibiting band shift. -ye, band shift not detected. Sds, splice donor site. eG:C to A:T
base transitions occurring at CpG dinucleotides. 'Predicted change in amino acid sequence as a result of mutation. g1CC, immunohistochemistry; +, < 10%
positive cells, focal staining pattern; ++, 10-50% positive cells; +++, > 50% positive cells, diffuse staining pattern; -ye, negative. hDI, DNA index.
Secondly, a number of studies have implicated p53 inactivation in adenocarcinoma and from 41 patients with adenocarcinoma of the
the malignant transformation of Barrett's oesophagus (Hamelin et gastric cardia. Barrett's-associated adenocarcinomas were catego-
al, 1994; Neshat et al, 1994; Gleeson et al, 1995). In order to rized as those tumours with histological evidence of having arisen
confirm and extend these observations, this study assessed the against abackground of Barrett's epithelium. All oesophageal cases
involvement ofp53 in premalignant Barrett's epithelium. were associated with Barrett's metaplasia extending greater than
3 cm into the oesophagus, and all tumours exhibited predominant
localization in the oesophagus. The gastric cardia tumours were
MATERIALS AND METHODS located near the gastro-o.esophageal junction. None had associated
Tissue collection and DNA extraction Barrett's epithelium. In six cases ofBar-rett's-associated adenocarci-
noma, residual Barrett's epithelium adjacent to adenocarcinoma was
Matched normnal and tumour tissue samples were obtained intra- obtained for analysis. The tissue was snap frozen in liquid nitrogen
operatively from 20 patients with Barrett's-associated oesophageal and stored at-70'C. The tissue samples werehistologically assessed
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Figure 1 Representative examples of allelic loss at the D1 7S796 locus on
chromosome 17p13. (1) Oase no. 50; (2) case no. 90; (3) case no. 99;
(4) case no. 112; (5) case no. 21; (6) case no. 31; (7) case no. 94; (8) case
no. 100; (9) case no.101; (10) caseno. 103; (11) caseno. 122; (12) case
no. 127. 0, control DNA; T, tumour DNA
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Figure 2 Diagrammatic representation of the p53mutation spectrum
detected in adenocarcinoma of the oesophagus and gastric cardia. Other,
insertions/deletions/splice site mutations
by a consultant pathologist (JMS) and classified according to the
procedure of Lauren (1965). Tumour stage was assessed using the
American Joint Committee on Cancer (A.J.C.C.) and the
International Union against Cancer (U.I.C.C.) criteria for patho-
logical staging (Hermanek and Sobin, 1987; Beahrs et al, 1988).
Cryostat sectioning was carried out to select tumour-rich tissue for
analysis, and microdissection was used to isolate all preneoplastic
lesions. DNA was extractedfrommatched normal and tumourtissue
samples as described previously (Gleeson et al, 1995).
Allelic loss analysis
To detect 17p allelic loss in the tumour tissue, two dinucleotide
repeat polymorphisms, D17S513 and D17S796, mapping to 17pl3
were analysed (Oliphant et al, 1990; Gyapay et al, 1994).
Polymerase chain reaction (PCR) amplification and microsatellite
analysis were carried out as described previously (Gleeson et al,
1995). LOH was scored by direct visual comparison ofthe relative
allelic ratios present in matched normal and tumour DNAs. Allele
loss was scored if one allele was absent or exhibited altered signal
intensity in tumourDNA relative to the allelic ratio ofnormal DNA.
Mutational analysis of p53, exons 5-8
For PCR amplification ofp53, exons 5-8, primers homologous to
sequences in the adjacent introns were used (Hsu et al, 1991, Table
1). Genomic DNA (300 ng) was incubated in a total volume of
100 gl of PCR buffer [50 mm potassium chloride, 10 mM Tris-
HCI, pH 9.0, 1 mm magnesium chloride (1.5 mm for exons 5 and
8), 0.1% Triton X-100] containing 0.25 gM ofeachprimer, 0.2 mm
C GOC A G N G C C T C
I'II II
I11~~~~~~~~~.
lr \
D
E G C0 A G N G C C T C 40
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Figure 3 Automated DNA sequence analysis of p53, exon 5 in patient no.
29. Wild-type p53sequence was detected in (A) control DNA and (B) non-
dysplastic intestinal metaplasia. A C to T substitution (antisense strand),
resulting in an arginine to histidine substitution, was detected at codon 175 in
(C) low-grade dysplasia, (D) high-grade dysplasia and (E) tumour. The
mutant allele is indicated by an arrow
dNTPs and 5 units of Taq polymerase (Promega). There was an
initial denaturation step at 940C for 5 min, followed by 35 cycles
of 1 min at 94°C, 1 min at 56°C (62°C for exon 6) and 30 s at
72°C, with a final extension step of72°C for 5 min.
A number ofp53 mutations (n = 19) were initially identified by
direct DNA sequencing on a subgroup of 35 tumours. Sequence
analysis was carried out as described previously (Gleeson et al,
1995). These 19 control mutations were analysed to select optimal
gel conditions for mutation detection by non-isotopic single-strand
conformational polymorphism (SSCP). For each exon, one set of
gel conditions was identified that detected all known sequence
variants in that exon. All exons were analysed on 1-mm-thick 8%
polyacrylamide gels with 2.6% cross-linking. The optimal condi-
tions selected were 4°C without glycerol (exon 6), 240C without
glycerol (exon 5) and 240C with 5% glycerol (exons 7 and 8).
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Table 4 Association between p53 gene mutation and 17p allelic loss in
oesophageal and gastric adenocarcinoma
17p Allelic loss
p53 Gene mutation LOH No LOH Fisher exact test
Mutation 33 3
No mutation 11 7 P= 0.02
Table 5 Association between p53 gene mutation and p53 protein
expression in oesophageal and gastric adenocarcinoma
p53 Protein expression
p53Gene mutation Diffuse FocaVnegative Chi-squared
Mutation 31 9
No mutation 6 12 P = 0.003
Table 6 Association between p53 missense mutation and p53 protein
expression in oesophageal and gastric adenocarcinoma
p53 Protein expression
p53 Missense mutation Diffuse Focal/negative Chi-squared
Missense mutation 31 0
No missense mutation 6 21 P < 0.0001
Aliquots of PCR product (5,l) were denatured in alkali buffer
(lOx stock: 500 mm sodium hydroxide, 10 mM EDTA) at 42°C for
30 min and immediately placed on ice. Loading buffer [lOx stock:
0.5% (w/v) bromophenol blue, 0.5% (w/v) xylene cyanol in deion-
ized formamide] was added and the samples were loaded to the
appropriate gel. Electrophoresis was performed at 400 V for 3-6 h
using 1 x TBE buffer. Electrophoresis was carried out using a
Protean II vertical electrophoresis tank (Biorad), which was
modified to allow buffer recirculation through a closed-circuit loop
placed in a temperature-regulated waterbath, allowing accurate and
reproducible temperature control. After electrophoresis, the gel
was fixed in an aqueous solution of 10% (v/v) ethanol and 0.5%
(v/v) acetic acid for 3 min (x2). The gel was stained in an aqueous
solution of 0.1% (w/v) silver nitrate for 15 min and visualized by
immersion in an aqueous solution of0.1% (w/v) sodium hydroxide
and 0.1% (v/v) formaldehyde for 20 min. The gel was fixed for
10 min in an aqueous solution of 0.75% (w/v) sodium carbonate.
Band shifts were identified by direct comparison of the pattem of
single-stranded bands in control and tumour DNA from the same
individual. SSCP analysis, using the optimized gel conditions, was
used to screen for p53 mutations in the remaining 26 cases.
Sequence analysis was used to confirm and identify the mutation
present in each sample exhibiting an altered mobility shift.
Immunohistochemistry
Paraffin sections (4 jm) were dewaxed in xylene, rehydrated
through descending grades of alcohol and immersed in 3% (v/v)
alcoholic hydrogen peroxide for 10 min. The sections were
immersed in 0.1 M sodium citrate buffer, pH 6.0, and microwaved
for 30 min. The sections were stained with the D07 antibody
(Novocastra) at an optimal dilution of 1:50 for 30 min at room
temperature and then rinsed in TBS to remove unbound primary
antiserum. A biotinylated anti-mouse secondary antiserum (Dako)
was incubated at an optimal dilution (1:200 in 1:25 normal human
serum) for 30 min at room temperature. The sections were rinsed
in TBS and the bound antiserum was visualized using the
streptavidin-biotin complex immunoperoxidase protocol, using
diaminobenzidine as a chromogen (Dako, UK). Sections were
counterstained in Harris's haematoxylin and mounted with DPX
mounting medium (Diachem). Sections demonstrating nuclear
staining in greater than 50% of tumour cells were categorized as
diffuse staining, while sections demonstrating nuclear staining in
less than 10% oftumourcells were categorized as focal staining. A
known strongly staining case was used as a positive control.
Omission ofthe primary antiserum served as a negative control.
Flow cytometry
Paraffin sections (50 ,um) were processed for flow cytometry using
a modification of the method described by Hedley et al (1983).
Nuclear suspensions were stained with propidium iodide solution
[propidium iodide (3 mg per 100 ml ofphosphate-buffered saline)
containing 10 mg ofRibonuclease A and 0.5 ml of0.5% Triton X-
100] at 4°C for 30 min. Samples were analysed on a Coulter Epics
Elite Flow Cytometerequipped with a 15-mW Argon laser, excita-
tion beam 488 nm. The DNA histogram upon which analysis was
performed in each case was gated on Forward Angle Light Scatter
(FALS) to minimize doublets and clumps, but included a propor-
tion of debris. The histograms were analysed using Multicycle
Software (Phoenix Flow Systems). This analysis allowed debris
and sliced nuclei to be accounted for and to be subtracted from the
histograms. Histograms that showed a single GOG, peak with a
corresponding G2 + M peak were classified as DNA diploid.
Diploid histograms were only accepted if the coefficient of varia-
tion (CV) at half the peak height was less than 10%. DNA aneu-
ploidy was defined as the presence ofan additionalGOG, peak that
contained > 10% of the total cell population. The DNA index,
defined as the modal DNA content ofthe aneuploid cell population
divided by the modal DNA content of the diploid cell population,
was calculated for each aneuploid histogram.
RESULTS
The mean age at diagnosis with oesophageal adenocarcinoma was
61 years (range 31-75 years), and the patient group demonstrated
a male-female ratio of 17:3. The tumour series included two stage
I tumours, 11 stage II tumours and seven stage III tumours. With
respect to histological subtype, the tumours included 19 cases of
the intestinal type (well-moderately differentiated, n = 12; poorly
differentiated, n = 7) and one poorly differentiated diffuse-type
adenocarcinoma (Table 2). The mean age at diagnosis with adeno-
carcinoma of the gastric cardia was 63 years (range 44-80 years),
and the patient group exhibited a male-female ratio of 31:10. The
tumour group included 11 stage II tumours and 30 stage III
tumours. Histological assessment identified 32 gastric adenocarci-
nomas of the intestinal type (well-moderately differentiated,
n = 17; poorly differentiated, n = 15) and nine gastric adenocarci-
nomas ofthe diffuse type (Table 3).
Allelic loss on chromosome 17p was investigated using two
highly informative dinucleotide repeat polymorphisms mapping to
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Figure 4 Representative examples of immunostaining pafterns obtained
with the D07 antiserum. (A) +, Focal staining of individual cell nuclei in
dysplastic Barrett's epithelium (original magnification x 400); (B) +++, diffuse
immunostaining of a moderately differentiated gastric adenocarcinoma, case
no. 92 (original magnification x 250); (C) +++, diffuse immunostaining in
dysplastic Barrett's epithelium, case no. 29 (original magnification x 100).
Intervening non-malignant stroma is immunonegative
chromosome l7p13. For oesophageal adenocarcinoma, 95% (19
of 20) of samples were informative at either one or both of the
polymorphic loci analysed, and allelic loss was detected in 79%
(15 of 19) of informative cases (Table 2). Allelic loss was detected
in 83% (29 of 35) of informative cases of gastric adenocarcinoma
(Table 3). With the exception ofcase no. 94, allele loss scores were
concordant in all cases for which both loci were informative.
Representative examples of allelic loss at the D17S796 microsatel-
lite are shown in Figure 1.
Mutational analysis ofp53, exons 5-8, resulted in the detection
of mutations in 70% (14 of 20) of oesophageal adenocarcinomas
(Table 2), eleven of which have been documented previously
(Gleeson et al, 1995). These included 12 missense mutations, one
non-sense mutation and one frameshift mutation, the last being a
2-bp deletion in exon 6. Eighty-five per cent (11 of 13) of the
single-base substitutions were G:C to A:T base transitions, with
69% (9 of 13) occurring at CpG dinucleotides. The remaining two
single-base changes were G:C to T:A base transversions.
Mutations were detected in 63% (26 of 41) of gastric adenocarci-
nomas (Table 3). These included 19 missense mutations, three
non-sense mutations, three splice site mutations and one deletion.
Of the 22 single-base substitutions in coding sequence, 82% (18 of
22) were base transitions (17 G:C to A:T, one A:T to G:C), with
55% (12 of 22) occurring at CpG dinucleotides. The remaining
four single-base substitutions were base transversions (two G:C to
T:A, one A:T to T:A, one A:T to C:G). A graphical representation
of the mutational profiles detected in oesophageal and gastric
adenocarcinoma is shown in Figure 2.
Premalignant Barrett's epithelium adjacent to oesophageal
adenocarcinoma was available for analysis in six cases (nos. 22,
29, 76, 108, 124 and 125). Sequence analysis did not detect a
mutation in case no. 125. In the remaining five cases, the same p53
mutation was detected both in high-grade dysplasia and in adja-
cent tumour tissue. In case no. 29, the same mutation was also
detected in low-grade dysplasia but not in Barrett's intestinal meta-
plasia (Figure 3). In case no. 108, low-grade dysplasia and
Barrett's intestinal metaplasia, negative for dysplasia, were not
found to contain the p53 mutation detected in the adjacent high-
grade dysplasia and tumour (Table 2).
Overall, 33 tumours with 17p allelic loss were found to contain
a p53 mutation. A further 11 cases exhibited 17p allelic loss,
however mutations were not detected in exons 5-8 of the p53
gene. p53 mutations were detected in three cases with retention
of heterozygosity on 17p and in four non-informative cases.
Mutations were not detected in seven cases that retained heterozy-
gosity on 17p nor in three non-informative cases. Statistical
analysis revealed an association between 17p allelic loss and p53
gene mutation (Table 4, Fisher exact test, P = 0.02).
p53 protein expression was assessed using the D07 antiserum,
and representative examples of the p53 immunostaining patterns
observed are shown in Figure 4. Weak cytoplasmic staining was
detected in focal cells in the basal layers of adjacent gastric
mucosa, squamous epithelium of the oesophagus and non-
dysplastic Barrett's epithelium. This staining was readily distin-
guished from the specific p53 nuclear immunostaining detected in
dysplastic epithelium and carcinoma. Omission of the primary
antiserum resulted in complete abolition of nuclear immuno-
staining. Diffuse p53 protein expression was detected in 65% (13
of 20) of oesophageal adenocarcinomas and in 59% (24 of 41)
of gastric adenocarcinomas. A further 21 cases exhibited focal
staining or negative p53 immunoreactivity. The remaining three
cases demonstrated immunoreactivity in 10-50% of tumour cells.
The staining pattern in these cases was not easily classified as
either diffuse (Figure 4B) or focal (Figure 4A). The significance of
p53 immunoreactivity in these cases is uncertain, and they were
excluded from subsequent statistical analyses. There was a signifi-
cant association between diffuse p53 protein expression and p53
gene mutation (Table 5; Chi-squared, P = 0.003). In particular, all
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31 missense mutations exhibited diffuse p53 protein expression,
while nine non-sense or truncating mutations were immunonega-
tive. Statistical analysis revealed a highly significant association
between diffuse p53 protein expression andp53 missense mutation
in these tumours (Table 6; Chi-squared, P < 0.0001).
There were six cases with premalignant Barrett's epithelium
adjacent to carcinoma, and in all cases the immunostaining pattern
in the dysplastic Barrett's epithelium was concordant with that
detected in the tumour tissue. Two cases (no. 108 and no. 125)
showed no immunostaining in either Barrett's epithelium or in
adjacent carcinoma. In the remaining four cases (nos. 22, 29, 76
and 124) diffuse p53 expression was detected in both premalignant
and malignant lesions; in each of these cases, sequence analysis
confirmed the presence of a missense mutation in both dysplastic
and invasive lesions (Table 2). Figure 4C shows an example of
diffuse p53 protein expression detected in dysplastic Barrett's
epithelium and in adjacent carcinoma.
DNA aneuploidy was detected in 80% (16 of20) ofoesophageal
tumours (Table 2) and in 70% (28 of40) ofgastric tumours (Table
3). Figure 5 shows representative examples of diploid and aneu-
ploid flow cytometric profiles. Allelic loss on 17p was associated
with the occurrence of DNA aneuploidy (Fisher exact test, P =
0.02). There was no association between DNA aneuploidy andp53
gene mutation or p53 protein expression.
There was no significant association between p53 gene abnor-
malities or DNA content abnormalities and tumour stage or histo-
logical subtype in either oesophageal or gastric adenocarcinoma.
DISCUSSION
The present study investigated the association between 17p allelic
loss, p53 gene mutation and p53 protein expression in a series of
adenocarcinomas arising in the oesophagus and gastric cardia. The
association between p53 gene abnormalities and DNA content in
these tumours was also assessed.
Uniformly high levels of 17p allelic loss, p53 gene mutation,
p53 protein expression and DNA aneuploidy were detected in both
adenocarcinoma of the oesophagus and gastric cardia. Similarly,
previous studies have documented 17p allelic loss in 69-100% of
oesophageal adenocarcinomas (Blount et al, 1991, 1993; Huang et
al, 1992). p53 gene mutations were reported in 55% (6 of 11) and
88% (15 of 17) of oesophageal adenocarcinomas (Hamelin et al,
1994; Neshat et al, 1994), while p53 protein expression was
detected in 53-87% of cases (Flejou et al, 1993; Hamelin et al,
1994; Hardwick et al, 1994). The presence of aneuploidy in
Barrett's oesophagus was reported to occur with increasing
frequency during the histological progression from metaplasia to
dysplasia and carcinoma (Reid et al, 1987; Haggitt et al, 1988).
Studies have consistently documented high levels of DNA aneu-
ploidy in oesophageal adenocarcinoma, typically ranging from
80% to 100% of cases (Reid et al, 1987; Nakamura et al, 1994).
A number of studies have reported a close association between
p53 overexpression in adenocarcinoma and in adjacent highly
dysplastic Barrett's epithelium (Flejou et al, 1993; Hardwick et al,
1994). Consistent with these observations, the present study iden-
tified five cases in which the samep53 gene mutation was present
in high-grade dysplasia and in adjacent carcinoma, suggesting that
p53 mutation preceded the development of invasive carcinoma in
these patients. Furthermore, in one of these cases (no. 29), the
samep53 gene mutation was also detected in coexisting low-grade
dysplasia, but not in adjacent non-dysplastic Barrett's epithelium.
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Figure 5 Representative DNA histograms of (A) a diploid tumour cell
population (case no. 109) and (B) an aneuploid tumour cell population (case
no. 101). Peak a, GoG1 of diploid cell population; peak b, G2 + M of diploid
cell population; peak c, GoG1 of aneuploid cell population; peak d, G2 + M of
aneuploid cell population
The detection of identical p53 mutations in high-grade dysplasia
and adjacent adenocarcinoma has been reported in two indepen-
dent studies (Hamelin et al, 1994; Neshat et al, 1994). One study
did not detect mutations in areas of low-grade dysplasia (n = 3)
and non-dysplastic Barrett's epithelium (n = 6) adjacent to carci-
noma (Hamelin et al, 1994). Similarly, in the present study, there
was one case (no. 108) in which thep53 mutation detected in high-
grade dysplasia and tumour was not detected in adjacent low-grade
dysplasia and non-dysplastic Barrett's epithelium. Therefore, to
date, p53 protein expression and p53 gene mutation have been
detected more frequently in high-grade dysplasia than in low-
grade dysplasia, suggesting thatp53 gene mutation may be associ-
ated with increasing severity ofdysplasia.
Between 37.5% and 68% ofgastric adenocarcinomas have been
reported to demonstrate 17p allelic loss (Sano et al, 1991; Seruca
et al, 1992; Ranzani et al, 1993). These values are lower than the
value of 83% noted in the present series of adenocarcinomas
arising in the gastric cardia. It is possible that site-specific differ-
ences (cardia vs antrum) may account for this higher frequency of
allelic loss. Studies have reported p53 mutations in 35-58% of
gastric carcinomas (Renault et al, 1993; Uchino et al, 1993; Shiao
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et al, 1994; Hongyo et al, 1995), and p53 protein expression has
been detected in 46-61% oftumours (Martin et al, 1992; Flejou et
al, 1994; Hongyo et al, 1995). DNA aneuploidy has been reported
in 40-50% of tumours (Yonemura et al, 1992; Brito et al, 1993).
However, studies in which tumours were analysed with respect to
anatomical site of origin have reported a number of site-specific
differences. A significantly higher level of p53 expression was
observed in gastric cardia tumours (56%, 20 of 36) compared with
tumours arising in the antrum (27%, 8 of 30) (Flejou et al, 1994).
Furthermore, a higher frequency of DNA aneuploidy was detected
in adenocarcinomas arising in the gastric cardia (Johnson et al,
1993; Flejou et al, 1994). For example, one study reported aneu-
ploidy in 76% (25 of 33) of adenocarcinomas arising in the gastric
cardia, compared with 30% (8 of 27) of adenocarcinomas arising
in the gastric antrum (Flejou et al, 1994). These molecular data are
consistent with reports that proximal and distal gastric tumours
display distinct clinical and epidemiological features. In general,
carcinomas ofthe gastric cardia have a poorer prognosis than those
of the gastric body, and their relative incidence appears to be
increasing (Sidoni et al, 1989; Blot et al, 1991). Conversely,
adenocarcinoma of the oesophagus and gastric cardia have been
reported to demonstrate similar clinicopathological parameters.
Both tumour types have demonstrated a parallel increase in inci-
dence rates (Blot et al, 1991). These tumours have been consis-
tently associated with a lower mean age, higher male-female ratio
and greater frequency of hiatal hernia than distal gastric tumours
(Kalish et al, 1984; Wang et al, 1986). The observation in this
study of similar frequencies ofp53 gene abnormalities and DNA
aneuploidy in these tumour types is consistent with the hypothesis
that they share a common aetiology.
The occurrence of p53 mutations early in the development of
oesophageal and gastric adenocarcinoma (Shiao et al, 1994)
suggests that the gene plays a central role in the control of normal
cell division at these sites. The oesophagus and stomach are easily
accessible and are likely to be exposed to many environmental
insults. p53-dependent pathways may play a vital role in
preserving molecular integrity by allowing damaged cells to
undergo repair or apoptosis. Cells that have acquired ap53 muta-
tion may have a selective advantage, being able to proliferate
under conditions of DNA damage that would be inhibitory in cells
with wild-type p53. These actively proliferating cells may be the
precursors ofneoplastic clones.
The detection of frequent mutations in a defined sequence has
been identified as a feature of mutational specificity (Thilly,
1990). It has been proposed that the comparison ofp53 mutation
spectra in tumours of different origin may reveal similarities or
differences concerning the endogenous and exogenous molecular
processes contributing to tumour development (Greenblatt et al,
1994). The observation of similar p53 mutation spectra in adeno-
carcinoma of the oesophagus and gastric cardia further suggests
similarities in the aetiologies ofthese cancers. Both tumour groups
demonstrated a predominance of base transitions at CpG dinu-
cleotides and a low frequency of base transversions. G:C to A:T
base transitions at CpG dinucleotides are thought to result from
spontaneous deamination of5'-methylcytosine, resulting in C to T
replacements (Coulondre et al, 1978). Other studies have reported
a predominance of base transitions at CpG dinucleotides in
Barrett's-associated adenocarcinoma (Hamelin et al, 1994; Neshat
et al, 1994). Furthermore, this spectrum ofp53 mutations is similar
to that previously described for both colorectal cancer (Baker et al,
1990) and gastric cancer (Renault et al, 1993; Uchino et al, 1993).
It has been reported that base transitions at CpG dinucleotides
account for 62.5% (20 of 32) and 67% (8 of 12) of single-base
substitutions in colorectal and gastric carcinoma respectively
(Baker et al, 1990; Renault et al, 1993). Conversely, although a
study by Hongyo et al (1995), in a high incidence area of gastric
cancer in Italy, detected G:C to A:T transitions in 93% (26 of
28) of cases with single-base substitutions, only 18% (5 of 28)
occurred at CpG dinucleotides. The different mutation spectrum in
the study of Hongyo et al (1995) may reflect site-specific
differences (cardia vs antrum) or regional exposure to particular
environmental agents.
It is generally accepted that the majority of missense mutations
generate a mutant protein with increased protein stability, thereby
facilitating detection by immunohistochemical techniques (Cripps
et al, 1994). Consistent with this, a highly significant association
was observed between missense mutation of the p53 gene and
diffuse p53 protein expression in both oesophageal and gastric
adenocarcinoma, with all 31 cases with missense mutations
exhibiting diffuse protein expression. A previous study of
oesophageal adenocarcinoma also reported a close correlation
between missense mutation and p53 protein expression (100%
agreement, 10 of 10) (Hamelin et al, 1994).
In the present study, there were six cases with diffuse p53
protein expression that were not found to contain a mutation in
exons 5-8 ofthep53 gene. There are a number ofpossibilities that
may account for the apparent discordance in these samples.
Firstly, mutations may have been missed by the screening tech-
niques used in the present study. Secondly, missense mutations
may lie in regions ofthe gene not screened in the present study. A
review of 50 studies that carried out sequencing of the entire
coding region of the p53 gene reported that 13% of mutations, up
to 30% of which were missense mutations, were located outside
exons 5-8 (Greenblatt et al, 1994). A third possibility is that mech-
anisms other than mutation resulted in the inactivation and stabi-
lization of p53 protein. Binding to viral oncoproteins, e.g. the
adenovirus E1B 55-kb protein, and cellular oncoproteins, e.g.
mdm2, has been shown to result in p53 stabilization and in the
inactivation ofwild-typep53 function (Yew and Berk, 1992; Wu et
al, 1993). In these instances, p53 overexpression represents the
functional, but not the structural, inactivation of the p53 gene. In
this respect, it was suggested that 'false positives' may not be
misleading in the biological sense ifthe stabilization ofp53 occurs
via a mechanism that also abolishes its function (Wynford-
Thomas, 1992).
None of 21 tumours with focal or negative immunostaining
were found to have a missense mutation, suggesting that focal
immunopositivity is not an indicator of mutational stabilization of
the p53 protein. However, truncating p53 mutations (non-sense
mutations, insertions/deletions and splice site mutations) were
detected in 14% (2 of 14) ofoesophageal adenocarcinomas and in
27% (7 of 26) of gastric adenocarcinomas studied. All nine trun-
cating mutations were immunonegative. These data indicate that a
proportion of immunonegative tumours may contain a mutation
that does not result in protein stabilization. It has been reported
that truncating mutations may account for as much as 37.5% of
mutations in oesophageal adenocarcinoma (Hamelin et al, 1994)
and 27% of mutations in gastric adenocarcinoma (Renault et al,
1993; Uchino et al, 1993). In these cases, immunohistochemical
assessment of p53 protein expression as a sole indicator of the
presence ofp53 gene mutation would result in an underestimation
of mutation frequency (false negatives). The observation of
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apparent discordance between molecular and immunohistochem-
ical analysis ofp53 gene mutation indicates that such techniques
should be regarded as complementary.
The acquisition of chromosomal rearrangements following the
loss of p53 function has been observed in a number of in vitro
systems (Livingstone et al, 1992; Yin et al, 1992). This suggests a
potential association between p53 gene abnormalities and the
development of genetic instability (Livingstone et al, 1992).
Evidence to support this hypothesis was provided by studies on
colorectal carcinoma in which DNA aneuploidy was shown to
be associated with 17p allelic loss (Offerhaus et al, 1992) and
increased p53 protein expression (Carder et al, 1993). Further-
more, Carder et al (1993) reported that the mean DNA index in
aneuploid tumours with stabilized p53 protein was significantly
higher than that in those aneuploid cases without stabilized
protein. In this study, statistical analysis demonstrated evidence of
an association between the presence of 17p allelic loss and DNA
aneuploidy (Fisher exact test, P = 0.02). However, the presence of
p53 gene mutation or p53 protein expression was not found to be
significantly associated with the occurrence ofDNA aneuploidy in
oesophageal and gastric adenocarcinoma. Furthermore, the mean
DNA index in aneuploid tumours with a p53 mutation was not
significantly higher than that in aneuploid cases without a p53
gene mutation. It is uncertain to what extent the association
between 17p allelic loss and abnormal DNA content reflects the
involvement of p53 inactivation in the development or establish-
ment ofaneuploid cell populations.
For both the oesophageal and gastric tumour series studied,
neither 17p allelic loss, p53 gene mutation, p53 protein expression
nor DNA aneuploidy exhibited an association with either tumour
stage orhistological subtype. This may reflect, in part, the predom-
inantly advanced stage of tumours in the present series. Similarly,
other studies on gastric adenocarcinoma have reported no associa-
tion between DNA ploidy and depth of tumour invasion or lymph
node metastasis (Yonemura et al, 1992; Brito et al, 1993). Studies
have reported an equal prevalence ofp53 mutations in early- and
late-stage gastric carcinoma (Uchino et al, 1993; Hongyo et al,
1995), and one study has reported the detection of the same p53
mutation in both tumour and adjacent dysplastic epithelium
in five cases of gastric adenocarcinoma (Shiao et al, 1994). In
oesophageal adenocarcinoma, no association has been reported
between p53 protein expression and tumour differentiation grade,
tumour stage (Flejou et al, 1993; Krishnadath et al, 1995) or lymph
node status (Flejou et al, 1993). Allelic loss on 17p, p53 gene
mutation and p53 protein expression have been documented in
dysplastic Barrett's epithelium (Flejou et al, 1993; Blount et al,
1994; Hardwick et al, 1994) and in both early and advanced adeno-
carcinomas (Blount et al, 1991; Flejou et al, 1993; Hamelin et al,
1994). These data suggest that p53 gene abnormalities may occur
early in the development of oesophageal adenocarcinoma. The
value of p53 as an intermediate biomarker in the identification of
patients at increased risk of malignant transformation in Barrett's
oesophagus awaits the outcome ofprospective follow-up studies.
In conclusion, the present study demonstrated uniformly high
levels ofp53 gene abnormalities and DNA aneuploidy in adeno-
carcinoma ofthe oesophagus and gastric cardia. Both oesophageal
and gastric tumours exhibited similar p53 mutation profiles, with
both tumour types being associated with a high frequency of base
transitions at CpG dinucleotides. The detection of similar molec-
ular alterations in adenocarcinoma of the oesophagus and gastric
cardia is consistent with the observation that these tumours also
exhibit similar clinical and epidemiological features. There was a
highly significant association between p53 missense mutation and
the presence of diffuse p53 protein expression in these tumours,
supporting the rationale for using immunohistochemical methods
as an indicator of missense mutation. However, truncating muta-
tions, which may account for a significant proportion ofp53 muta-
tions in oesophageal and gastric tumours, can not be detected by
immunohistochemical techniques. Allelic loss on 17p, p53 gene
mutation and p53 protein expression were each detected in pre-
malignant Barrett's epithelium. Future prospective studies should
determine the clinical relevance of p53 gene alterations as an
independent marker of Barrett's patients at an increased risk of
neoplastic transformation.
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